Lung Cancer Vaccine to Come to the US
The vaccine targets the naturally occuring epidermal growth factor (EGF). This protein attaches to the receptor proteins on cell surfaces and signals for the cell to grow and divide. Some cancers cause the body to overproduce EGF, meaning cells begin to grow and divide uncontrollably. The vaccine stimulates an immune response, creating antibodies to bind to EGF, and preventing it’s attachment to the receptors on cancer cells, therefore slowing its growth.
Previous Trials A few small trials have resulted in some promising evidence supporting the efficacy of CimaVax. One randomized control study investigated 80 individuals who had been diagnosed with stage 3b and 4 who were administered complete chemotherapy treatment before half of the sample group were given the vaccine. The objectives of these phase 2 trials were to determine if the vaccine improved life expectancy, as well as observing side effects and immune responses.
The Future of CimaVax